Single-round infectious rotavirus and use thereof
Single-infectious rotavirus strains with targeted mutations in structural proteins and foreign gene expression address the safety concerns of existing rotavirus vaccines, enabling safer vaccine development and neutralization tests.
Patent Information
- Application Number
- PCT/JP2024/019050
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-31
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current rotavirus vaccines, particularly live attenuated vaccines, face challenges such as potential reversion to pathogenicity and the lack of single-infectious rotavirus strains for research and vaccine development.
Development of single-infectious rotavirus strains with specific mutations in proteins like VP1, VP2, VP3, VP4, VP6, VP7, NSP2, NSP3, and NSP4, which are characterized by dysfunction in structural proteins, and the introduction of foreign genes or reporter genes for safer vaccine development and neutralization tests.
The creation of single-infectious rotavirus strains ensures they cannot form infectious particles after a single infection, making them safe for use in vaccine development and neutralization tests, while expressing foreign genes or reporter proteins for enhanced functionality.
Smart Images

Figure JP2024019050_28112024_PF_FP_ABST
Abstract
Description
Single infectious rotavirus and its uses
[0001] The present invention relates to a monoinfectious rotavirus, a rotavirus vaccine containing the monoinfectious rotavirus, and a rotavirus neutralization test method using the monoinfectious rotavirus.
[0002] Rotavirus, a member of the Reoviridae family, is known as a virus that causes diarrhea in infants and young children. Infants between 6 months and 2 years of age are most susceptible to rotavirus infection and disease, with nearly 100% infected by the age of 5. A live attenuated rotavirus vaccine is available and is designated as a routine vaccination in Japan under the Vaccination Act. While the preventive effect of live attenuated rotavirus vaccines has been confirmed, there have been reports of the virus spreading into the environment and the virus reverting to pathogenicity.
[0003]
[0003] Single-episode infectious viruses are not only useful for basic research such as elucidating the viral life cycle, but are also expected to be applied to the development of safer next-generation vaccines. The present inventors have developed a practical method for artificially synthesizing rotavirus (reverse genetics system) (Patent Document 1, Non-Patent Document 1), and this technology has made it possible to produce artificial recombinant rotaviruses with any mutation or artificial recombinant rotaviruses carrying foreign genes. However, there have been no reported cases of single-episode infectious rotaviruses.
[0004] International Publication WO2018 / 062199
[0005] Kanai et al., Proc Natl Acad Sci US A. 2017 Feb 28; 114(9):2349-2354
[0006] An objective of the present invention is to provide a single-infectious rotavirus. A further objective of the present invention is to provide a rotavirus vaccine containing the single-infectious rotavirus and a method for rotavirus neutralization testing using the single-infectious rotavirus.
[0007] In order to solve the above-mentioned problems, the present invention encompasses the following inventions: [1] A single-episode infectious rotavirus characterized by having a mutation in at least one viral protein selected from the group consisting of rotavirus VP1, VP2, VP3, VP4, VP6, VP7, NSP2, NSP3, and NSP4. [2] The single-episode infectious rotavirus according to [1] above, which has a mutation that induces dysfunction of a structural protein. [3] The single-episode infectious rotavirus according to [1] or [2] above, which has a mutation in VP6. [4] The single-episode infectious rotavirus according to [3] above, which has a mutation in domain H of VP6. [5] The single-episode infectious rotavirus according to [4] above, which has a mutation in the A'-A'' loop, the D'-D'' loop, or the αA-I loop of domain H of VP6. [6] The single-episode infectious rotavirus according to [1] or [2] above, which has a mutation in VP4. [7] The single-infectious rotavirus according to [6] above, which has a mutation that deletes the lectin domain and / or the β-barrel domain of VP4. [8] The single-infectious rotavirus according to [1] or [2] above, which has a mutation in VP7. [9] The single-infectious rotavirus according to [8] above, which has a mutation that deletes domain II of VP7.
[10] The single-infectious rotavirus according to any of [1] to [9] above, which is a reassortant.
[11] The single-infectious rotavirus according to any of [1] to [9] above, which is a reassortant having a segmented RNA genome encoding structural proteins of a genotype different from that of the parent strain or structural proteins of a strain different from that of the parent strain.
[12] The single-infectious rotavirus according to any of [1] to [9] above, which is a reassortant having a segmented RNA genome encoding structural proteins of a human rotavirus.
[13] The single-infectious rotavirus according to any of [1] to
[12] above, which expresses a foreign gene.
[14] The single-infectious rotavirus according to
[13] above, wherein the foreign gene is a gene encoding an antigenic protein of a virus or a pathogenic microorganism other than rotavirus.
[15] The single-infectious rotavirus according to
[13] above, wherein the foreign gene is a reporter gene.
[16] The single-infectious rotavirus according to
[15] above, wherein the reporter gene is a gene encoding a fluorescent protein or a chemiluminescent protein.
[17] A vaccine containing the monoinfectious rotavirus according to any one of [1] to
[14] above.
[18] The vaccine according to
[17] above, which is a rotavirus vaccine.
[19] A method for neutralizing rotavirus, characterized by using the monoinfectious rotavirus according to any one of [1] to
[16] above.
[0008] The present invention can provide a mono-infectious rotavirus, a rotavirus vaccine containing the mono-infectious rotavirus, and a rotavirus neutralization test method using the mono-infectious rotavirus.
[0009] 1 shows the domain structure of VP6 and the mutated region of the mutant VP6 used in Example 1. It shows the results of measuring the viral titer of 18 types of artificial recombinant rotaviruses into which mutations have been introduced into VP6. It shows the results of comparing the proliferation ability of VP6-sustained expressing cells and non-VP6-expressing cells infected with 9 types of artificial recombinant rotaviruses that showed high titers in Example 1. It shows the results of comparing the proliferation ability of VP6-sustained expressing cells and non-VP6-expressing cells infected with the artificial recombinant rotavirus Δ169-174+linker selected in Example 2, where (A) shows the results for non-VP6-expressing cells and (B) shows the results for VP6-sustained expressing cells. It shows the results of examining the proliferation ability of non-VP6-expressing cells infected with the artificial recombinant rotavirus Δ169-174+linker and passaged the virus five times.
[0033] Figure 1 shows the results of infecting cells that do not express VP6 with the single-pass infectious rotavirus Δ169-174 + linker and wild-type simian rotavirus, respectively, and observing the expression of NSP4 and VP6 by immunofluorescence antibody analysis. Figure 2 shows the results of infecting cells that persistently express VP6 with a single-pass infectious rotavirus that expresses green fluorescent protein (ZsG), which was prepared by inserting a gene encoding green fluorescent protein (ZsG) into the RNA genome segment encoding NSP1 in the single-pass infectious rotavirus Δ169-174 + linker, and with the single-pass infectious rotavirus Δ169-174 + linker that does not express green fluorescent protein, respectively, and observing the expression of ZsG and NSP4. 1 shows the results of measuring luciferase activity over time after infecting cells persistently expressing VP6 with a luciferase-expressing single-infectious rotavirus (Δ169-174+linker) prepared by inserting a gene encoding luciferase (NLuc) into the RNA genome segment encoding NSP1 in the single-infectious rotavirus Δ169-174+linker, and with a single-infectious rotavirus that does not express luciferase. 1 shows the results of neutralization tests of luciferase-expressing single-infectious rotavirus and luciferase-expressing self-replicating rotavirus without a mutation in VP6 using mouse serum immunized with wild-type simian rotavirus SA11 strain.
[0023] Figure 1 shows the results of measuring the virus titer after producing five types of single-infectious rotavirus Δ169-174+linker having segmented RNA genomes encoding human rotavirus VP7. Figure 2 shows the results of a neutralization test of single-infectious rotaviruses having segmented RNA genomes encoding four types of human rotavirus VP7 using serum from mice immunized with wild-type simian rotavirus SA11 strain. Figure 3 shows the results of a neutralization test of vaccine efficacy in which mice were orally administered three times with single-infectious rotavirus Δ169-174+linker, and blood was collected two weeks after each administration.
[0024] Figure 4 shows the structure of rotavirus (A) and the structure of VP6 (B).
[0010]
[0023] Figure 1 shows the results of orally administering single-dose infectious rotavirus Δ169-174+linker or wild-type rotavirus to mice, recovering the intestinal tract two days later, and examining the virus copy number and the presence or absence of infectious virus. (A) shows the results of measuring the virus copy number in the cecum, and (B) shows the results of infecting VP6-expressing MA104 cells with cecal homogenate and measuring the virus titer. (A) shows the structure of rotavirus VP7, and (B) shows the mutated region of the mutant VP7 used in Example 12.
[0024] Figure 1 shows the results of infecting VP7-sustained expressing cells and non-VP7-expressing cells with the artificial recombinant rotavirus VP7-ΔDomain II prepared in Example 12, and comparing their growth potential. (A) shows the results for non-VP7-expressing cells, and (B) shows the results for persistent VP7-expressing cells.
[0025] Figure 1 shows the results of infecting non-VP7-expressing cells with artificial recombinant rotavirus VP7-ΔDomain II, and examining their growth potential after five repeated virus passages. (A) is a diagram showing the structure of rotavirus VP4, and (B) is a diagram showing the mutated region of the mutant VP4 used in Example 15. Figure 1 shows the results of comparing the proliferation ability of cells that continuously express VP4 and cells that do not express VP4 infected with the artificial recombinant rotavirus VP4-120bp prepared in Example 15, where (A) shows the result for cells that do not express VP4, and (B) shows the result for cells that continuously express VP4. Figure 1 shows the results of examining the proliferation ability of cells that do not express VP4 infected with the artificial recombinant rotavirus VP4-120bp and passaged the virus five times. This figure shows the results of infecting cells that do not express VP4 with a green fluorescent protein-expressing single-infectious rotavirus, which was created by inserting a gene encoding green fluorescent protein (ZsG) into the segmented RNA genome of a single-infectious rotavirus VP4-120bp in which most of the VP4 gene had been deleted, and a single-infectious rotavirus (VP4-120bp) that does not express green fluorescent protein, and observing the expression of ZsG and NSP4.This figure shows the results of infecting cells that do not express VP4 with a luciferase-expressing single-infectious rotavirus, which was created by inserting a gene encoding luciferase (NLuc) into the segmented RNA genome of a single-infectious rotavirus VP4-120bp in which most of the VP4 gene had been deleted, and a single-infectious rotavirus (VP4-120bp) that does not express luciferase, and measuring luciferase activity over time. This figure shows the results of infecting cells that do not express VP4 with an RBD-expressing single-episode rotavirus (VP4-120bp-RBD) created by inserting a gene encoding the receptor binding domain (RBD) of the spike protein of the novel coronavirus (SARS-CoV-2) into the segmented RNA genome of a single-episode rotavirus VP4-120bp from which most of the VP4 gene had been deleted, and a single-episode rotavirus that does not express RBD (VP4-120bp), and then observing the expression of RBD and NSP3 by Western blotting.
[0011] The present invention provides a mono-infectious rotavirus. As used herein, "mono-infectious rotavirus" refers to a rotavirus that is unable to form infectious virus particles after a single infection, or whose production of infectious virus particles is suppressed after a single infection. Furthermore, "mono-infectious rotavirus" refers to a rotavirus whose viral titer decreases with subculture. A mono-infectious rotavirus can form infectious virus particles and grow when it infects cells that express normal viral proteins corresponding to the viral proteins into which a mutation has been introduced, but it cannot grow when it infects normal cells, making it safe and preventing it from spreading in the environment.
[0012] Rotavirus is a non-enveloped virus belonging to the Reoviridae family. The virus particle has a triple structure consisting of an outer coat, an inner coat, and a core protein, and contains a double-stranded RNA genome consisting of 11 segments (see Figure 13(A)). These 11 gene segments encode six structural proteins (VPs) and six non-structural proteins (NSPs) (Table 1).
[0013]
[0014] The single-infectious rotavirus of the present invention may have a mutation in at least one viral protein selected from the group consisting of rotavirus VP1, VP2, VP3, VP4, VP6, VP7, NSP2, NSP3, and NSP4. As shown in Table 1, VP1, VP2, VP3, VP4, VP6, and VP7 are structural proteins of rotavirus, and NSP2, NSP3, and NSP4 are nonstructural proteins. The single-infectious rotavirus of the present invention may have a mutation in a rotavirus structural protein, or may have a mutation that induces dysfunction of a structural protein.
[0015] The number of viral proteins having a mutation may be two or more, or may be one, but is preferably one. The structural protein having a mutation may be VP6 (inner capsid protein). When the structural protein having a mutation is VP6, it is preferable that the mutation be in a region that interacts with VP7 (outer capsid protein). The region that interacts with VP7 may be domain H of VP6. Domain H contains three loop structures (A'-A'' loop, D'-D'' loop, and αA-I loop), and any one of these loops may have a mutation.
[0016] The structural protein having a mutation may be VP4 (spike protein). When the structural protein having a mutation is VP4, the mutant VP4 may be a deletion of the lectin domain, a deletion of the β-barrel domain, or a deletion of both the lectin domain and the β-barrel domain. The larger the deleted region, the less likely reversion occurs and the easier it is to introduce a foreign gene; therefore, it is preferable that the mutant VP4 be a deletion of both the lectin domain and the β-barrel domain. A mutant VP4 lacking both the lectin domain and the β-barrel domain of VP4 may be a mutant VP4 in which at least 30 bp, 40 bp, 50 bp, 60 bp, 70 bp, 80 bp, 90 bp, 100 bp, or 120 bp or more remain at the N-terminus and at least 30 bp, 40 bp, 50 bp, 60 bp, 70 bp, 80 bp, 90 bp, 100 bp, or 120 bp or more remain at the C-terminus in the base sequence of the genomic segment encoding VP4. The number of bases remaining at the N-terminus and C-terminus is not particularly limited, and the number of bases on both sides does not need to be the same.
[0017] The structural protein having a mutation may be VP7 (coat protein). When the structural protein having a mutation is VP7, it may be a VP7 having a deletion of domain II. A mutant VP7 having a deletion of domain II of VP7 may be a VP7 having at least 200 bp, 210 bp, 220 bp, 230 bp, 240 bp, or 250 bp or more remaining at the N-terminus and at least 200 bp, 210 bp, 220 bp, 230 bp, 240 bp, or 250 bp or more remaining at the C-terminus. The number of bases remaining at the N-terminus and C-terminus is not particularly limited, and the number of bases on both sides does not need to be the same.
[0018] The type of mutation is not particularly limited, and examples include amino acid deletion and amino acid substitution. The number of amino acids to be deleted or substituted is not particularly limited, and may be 100 or less, 50 or less, 40 or less, 30 or less, 20 or less, or 10 or less. The amino acid substitution may be an alanine substitution, or may be an arbitrary amino acid linker. Mutation introduction into a structural gene can be carried out using known gene recombination techniques.
[0019] The monoinfectious rotavirus of the present invention can be produced using known methods for producing artificial recombinant rotaviruses. For example, the methods described in Patent Document 1 (WO2018 / 062199) and Non-Patent Document 1 (Kanai et al., Proc Natl Acad Sci USA. 2017 Feb 28; 114(9):2349-2354), or partially modified versions of these methods, can be suitably used. It is preferable to transfect the host cells with a normal protein expression vector corresponding to the mutated viral protein. A capping enzyme expression vector, a FAST (fusion-associated small transmembrane) protein expression vector, a rotavirus NSP2 expression vector, a rotavirus NSP5 expression vector, or the like may also be appropriately selected and transfected into the host cells. For example, the method for producing an artificial recombinant rotavirus described in Example 1 of the present application may be used.
[0020] Examples of the capping enzyme that can be used include vaccinia virus capping enzyme. Examples of the FAST protein that can be used include Nelson Bay reovirus p10 and avian reovirus p10. Host cells that are highly susceptible to rotavirus and have high gene transfer efficiency are suitable. Examples include BHK cells, MA104 cells, COS7 cells, CV1 cells, Vero cells, L929 cells, 293T cells, and A549 cells.
[0021] Whether the artificial recombinant rotavirus produced is a single-infectious rotavirus can be determined by infecting the produced artificial recombinant rotavirus into cells that express a normal structural protein corresponding to the structural protein into which a mutation has been introduced and cells that do not express the structural protein, and confirming that the virus grows when infected with the former but does not grow when infected with the latter.
[0022] The monoinfectious rotavirus of the present invention may be a reassortant (genetic reassortant). A rotavirus reassortant is a rotavirus with a new genotypic structure resulting from recombination of segmented RNA genomes between different rotavirus species or strains. Reassortants are useful for functional analysis of segmented genomes and are extremely useful as artificial recombinant rotavirus vaccine candidates. The segmented RNA genome to be recombined may be a segmented RNA genome encoding a structural protein of a genotype different from that of the parent strain. There are numerous genotypes for each of the 11 gene segments of rotavirus; for example, 42 types of G type (VP7) and 58 types of P type (VP4) have been reported. These genotypes are expected to continue to increase. The segmented RNA genome to be recombined may be a segmented RNA genome encoding a structural protein of a strain different from that of the parent strain. The genotype of the structural protein of the strain different from that of the parent strain may be the same as or different from that of the parent strain. Furthermore, the segmented RNA genome to be recombined may be a segmented RNA genome encoding a structural protein of a human, non-human mammalian, or avian rotavirus, or may be a segmented RNA genome encoding a structural protein of a genotype different from that of the parent strain of a human, non-human mammalian, or avian rotavirus.
[0023] The structural proteins of a heterologous or heterologous strain of rotavirus used to prepare reassortants may be any structural proteins other than those of the parent strain that have a mutation. For example, in the case of a single-episode infectious rotavirus having a mutation in VP6 (inner capsid protein), the reassortant preferably has a segmented RNA genome encoding VP7 (outer capsid protein) and / or VP4 (spike protein) of the heterologous or heterologous strain of rotavirus. In the case of a single-episode infectious rotavirus having a mutation in VP4, the reassortant preferably has a segmented RNA genome encoding VP7 and / or VP6 of the heterologous or heterologous strain of rotavirus. In the case of a single-episode infectious rotavirus having a mutation in VP7, the reassortant preferably has a segmented RNA genome encoding VP4 and / or VP6 of the heterologous or heterologous strain of rotavirus. Preferably, the heterologous rotavirus is a human rotavirus. By recombining the RNA segments encoding the structural proteins of human rotavirus, single-infectious rotaviruses having the antigenicity of various genotypes (serotypes) of human rotavirus can be produced. Such single-infectious rotaviruses having the antigenicity of various genotypes (serotypes) of human rotavirus are very useful as vaccine antigens for rotavirus vaccines and as antigens for neutralization tests.
[0024] The single-episode infectious rotavirus of the present invention may be a single-episode infectious rotavirus that expresses a foreign gene. A single-episode infectious rotavirus that expresses a foreign gene can be produced by expressing the foreign gene into at least one of the segmented RNA genomes. The foreign gene is not particularly limited, and a single-episode infectious rotavirus that expresses any foreign gene can be produced. For example, by expressing a foreign gene encoding an antigen protein of a virus or pathogenic microorganism other than rotavirus, the produced single-episode infectious rotavirus can be used as a vaccine. Examples of viruses and pathogenic microorganisms other than rotavirus include norovirus, adenovirus, hepatitis A virus, sapovirus, hand, foot, and mouth disease virus, enterovirus, HIV, coronavirus, novel coronavirus (SARS-CoV-2), Salmonella, Campylobacter, Vibrio parahaemolyticus, Escherichia coli O157, Vibrio cholerae, Salmonella typhi, and Shigella. These vaccine antigens may be epitope peptides. A vaccine may be constructed by combining multiple artificial recombinant rotaviruses that express different foreign vaccine antigens.
[0025] The foreign gene may be an antigenic protein (e.g., VP4, VP7, etc.) of a heterologous or heterologous rotavirus strain. By expressing one or more antigenic proteins of heterologous or heterologous rotavirus strains, a single-dose infectious rotavirus that can be used as a multivalent rotavirus vaccine can be provided. The antigenic protein may be an epitope peptide.
[0026] The foreign gene may be a reporter gene. There is no particular limitation on the reporter gene, as long as it is a commonly used one. Examples of the reporter gene include genes encoding fluorescent proteins, chemiluminescent proteins, β-galactosidase, β-glucuronidase, chloramphenicol acetyltransferase, alkaline phosphatase, peroxidase, etc. The reporter gene may be a gene encoding a fluorescent protein or a chemiluminescent protein.
[0027] Examples of fluorescent proteins include, but are not limited to, green fluorescent protein, blue fluorescent protein, cyan fluorescent protein, yellow-green fluorescent protein, yellow fluorescent protein, orange fluorescent protein, red fluorescent protein, etc., and known fluorescent proteins can be suitably used. Examples of chemiluminescent proteins include, but are not limited to, luciferase, aequorin, obelin, etc., and known chemiluminescent proteins can be suitably used.
[0028] Single-infectious rotaviruses expressing a reporter gene allow easy visualization of viral load, and can be used for rotavirus neutralization tests and screening of anti-rotavirus drugs, which are safer and easier to perform than using self-replicating rotaviruses.
[0029] [Vaccine] The mono-infectious rotavirus of the present invention can be used as a vaccine. That is, the present invention provides a vaccine using the mono-infectious rotavirus of the present invention. As described above, the mono-infectious rotavirus of the present invention, mono-infectious rotavirus (reassortant) having a segmented RNA genome encoding the structural proteins of human rotavirus, and mono-infectious rotavirus expressing a foreign gene encoding an antigenic protein of a heterologous species or strain of rotavirus can be suitably used as a rotavirus vaccine. Furthermore, a polyvalent rotavirus vaccine can be constructed by mixing multiple mono-infectious rotaviruses expressing antigenic proteins of rotaviruses of different genotypes (serotypes).
[0030] As described above, single-episode infectious rotaviruses that express foreign genes encoding antigenic proteins of viruses or pathogenic microorganisms other than rotavirus can be suitably used as vaccines against various viruses and pathogenic microorganisms. A vaccine may be constructed by combining multiple single-episode infectious rotaviruses that express different foreign antigenic proteins.
[0031] [Neutralization test method] The single-infectious rotavirus of the present invention can be used in a rotavirus neutralization test. That is, the present invention provides a rotavirus neutralization test method using the single-infectious rotavirus of the present invention. A rotavirus neutralization test can be carried out by mixing serially diluted test serum with the single-infectious rotavirus of the present invention to cause an antigen-antibody reaction, inoculating the mixture into cultured cells on a microplate, and culturing the mixture, and then measuring the number of virus-infected cells.
[0032] The neutralization test method of the present invention preferably uses a single-episode infectious rotavirus that expresses a reporter gene. By using a single-episode infectious rotavirus that expresses a reporter gene, the number of virus-infected cells can be measured based on the expression level of the reporter protein, allowing for a simple, safe neutralization test with minimal fluctuations.
[0033] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.
[0034] Example 1: Production of a monoinfectious rotavirus by VP6 mutation introduction Materials and methods (1) Virus The simian rotavirus SA11 strain (hereinafter referred to as "SA11 strain") was used (see Table 1).
[0035] (2) Plasmids Containing Expression Cassettes for Each RNA Genome Segment of the SA11 Strain (Segmented RNA Genome Expression Vectors) Plasmids containing cDNAs for the 11 RNA genome segments of the SA11 strain were prepared according to the method described in WO2018 / 062199 (Patent Document 1). RT-PCR was performed using double-stranded RNA extracted from the virus as a template and specific primers based on the nucleotide sequence of each RNA genome segment. The resulting RT-PCR products (cDNAs for each RNA genome segment) were inserted between the T7 promoter sequence and hepatitis D virus (HDV) ribozyme sequence of the p3E5 plasmid to obtain plasmids containing expression cassettes for each RNA genome segment. The expression cassettes for each RNA genome segment consisted of a T7 promoter sequence on the 5' side of the cDNA for each RNA genome segment, an HDV ribozyme sequence on the 3' side, and a T7 terminator sequence downstream. The constructed plasmids (segmented RNA genome expression vectors) are designated pT7-VP1SA11, pT7-VP2SA11, pT7-VP3SA11, pT7-VP4SA11, pT7-VP6SA11, pT7-VP7SA11, pT7-NSP1SA11, pT7-NSP2SA11, pT7-NSP3SA11, pT7-NSP4SA11, and pT7-NSP5SA11, respectively.
[0036] (3) Capping Enzyme Expression Vectors As described in Kanai et al. (Proc Natl Acad Sci USA 2017 Feb 28;114(9):2349-2354), the protein coding region DNA of the vaccinia virus D1R gene (GenBank ACCESSION No.: NC006998, positions 93948-96482) and the protein coding region DNA of the vaccinia virus D12L gene (GenBank ACCESSION No.: NC006998, positions 107332-108195) were inserted into the Bg1II cleavage site of the pCAGGS plasmid to prepare pCAG-D1R (vaccinia virus mRNA capping enzyme large subunit expression vector) and pCAG-D12L (vaccinia virus mRNA capping enzyme small subunit expression vector).
[0037] (4) Rotavirus VP6 Expression Vector The VP6 expression vector, pcDNA3-VP6, was prepared by inserting the protein-coding region DNA of the SA11 strain VP6 gene (SEQ ID NO: 6) into the BamHI and EcoRI cleavage sites of the pcDNA3.1(+) plasmid. The coding region DNA was synthesized using an artificial gene synthesis service (GenScript).
[0038] (5) Rotavirus NSP2 and NSP5 Expression Vectors. The NSP2 and NSP5 expression vectors were prepared by inserting the protein-coding DNA of the SA11 strain NSP2 gene (SEQ ID NO: 8) and the protein-coding DNA of the NSP5 gene (SEQ ID NO: 11) into the EcoRI site of the pCAGGS plasmid, respectively, to create pCAG-NSP2 and pCAG-NSP5. Each coding region DNA was synthesized by an artificial gene synthesis service (Eurofins Genomics). Each synthetic DNA was inserted into the EcoRI site of the pCAGGS plasmid, creating pCAG-NSP2 and pCAG-NSP5.
[0039] (6) VP6 Mutation-Introducing Plasmids Eighteen types of plasmids were constructed using known genetic recombination techniques, with various mutations introduced into the cDNA of the rotavirus VP6 RNA genome contained in pT7-VP6SA11. The domain structure of rotavirus VP6 and the various mutated regions are shown in Figure 1. Specific mutations are listed in Table 2.
[0040]
[0041] (7) T7 RNA polymerase-sustaining expressing cells: BHK-T7 / P5 cells, which continuously express T7 RNA polymerase, were used. BHK-T7 / P5 cells were generated by transfecting BHK (Baby Hamster Kidney) cells with the pCAGGS plasmid, which contained DNA encoding T7 RNA polymerase downstream of the CAG promoter, and culturing the cells in an antibiotic-containing medium for selection.
[0042] (8) VP6-persistently expressing cells. The rotavirus VP6 gene was introduced into the pLVSIN-CMV-Neo vector (Takara Bio) and co-transfected with psPAX2 (Addgene) and pCMV-VSV-G (Addgene) into 293T cells to generate lentivirus. The resulting lentivirus was infected into African green monkey MA104 cells (ATCC CRL-2378.1). Two days later, drug selection was performed with G418 (800 μg / mL). From the VP6-expressing MA104 cells obtained through drug selection, the cells with the strongest VP6 expression were cloned by limiting dilution. After four rounds of limiting dilution, MA104 cells with persistent VP6 expression were obtained.
[0043] (9) Preparation of artificial recombinant virus The day before transfection, 5 × 10 BHK-T7 / P5 cells were cultured in a 5 × 10 4 Cells were seeded at 1000 cells / well in a 12-well culture plate. The next day, 10 types of segmented RNA genome expression vectors (pT7-VP1SA11, pT7-VP2SA11, pT7-VP3SA11, pT7-VP4SA11, pT7-VP7SA11, pT7-NSP1SA11, pT7-NSP2SA11, pT7-NSP3SA11, pT7-NSP4SA11, and pT7-NSP5SA11), mutagenized pT7-VP6SA11, capping enzyme expression vectors (pCAGD1R and A total of 16 plasmids, including pCAG-D12L, rotavirus NSP2 expression vector (pCAG-NSP2SA11), rotavirus NSP5 expression vector (pCAG-NSP5SA11), and rotavirus VP6 expression vector (pcDNA3-VP6), were transfected into BHK-T7 / P5 cells at 0.125 μg each (2 μg total) using a transfection reagent (TransIT-LT1 (trade name), Mirus). 2 μL of transfection reagent was used per μg of DNA. BHK-T7 / P5 cells were cultured in DMEM medium containing 5% FBS, 100 units / mL penicillin, and 100 μg / mL streptomycin at 37°C under a 5% CO2 environment. 24 hours after transfection, the medium was replaced with FBS-free, trypsin-containing medium, and 2 × 10 MA104 cells persistently expressing VP6 were transfected. 5Cells were added at 1000 cells / well and co-cultured for 5 days, after which the medium and cells were collected. The collected medium and cells were frozen and thawed three times to prepare a cell lysate. 10% of the obtained cell lysate was transferred to freshly prepared MA104 cells (2 × 10 5 The medium and cells were then frozen and thawed three times to prepare cell lysates, which were then transferred to MA104 cells (1 × 10 cells / well, 12-well culture plate) and cultured for another 5 days. 4 The virus was added to cells (cells / well, 96-well culture plate) and fixed with formalin after 18 hours. The membrane was permeabilized with 0.5% Triton-X, and infected cells were visualized by immunofluorescence. The primary antibody used for immunofluorescence was a rabbit anti-rotavirus NSP4 antibody (J Virol. 2023 Jan 31;97(1):e0186122.), and the secondary antibody was a CF488-labeled anti-rabbit IgG antibody (Biotum). Confirmation of infected cells indicated that the recombinant virus had been produced.
[0044] (10) Measurement of viral titer: VP6-sustained MA104 cells were cultured at 1 × 10 4 Cells were seeded at 1000 cells / well in a 96-well culture plate and cultured overnight. 15 μL of cell lysate was added to 135 μL of saline and vortexed to prepare a 10-fold dilution. This procedure was repeated to prepare serially diluted virus samples. 50 μL / well of serially diluted virus samples were added to MA104 cells persistently expressing VP6. After 18 hours, the cells were fixed with formalin. After membrane permeabilization with 0.5% Triton-X, infected cells were visualized by immunofluorescence. The primary antibody used in the immunofluorescence assay was the same rabbit anti-rotavirus NSP4 antibody as described above (9), and the secondary antibody was a CF488-labeled anti-rabbit IgG antibody. The number of infected cells was counted to calculate the virus titer.
[0045] <Results> The results are shown in Figure 2. Artificial recombinant viruses were successfully produced using 18 types of VP6 mutation-introduced plasmids. Among the three types of loop structures of rotavirus VP6, partial deletion mutations, alanine substitution mutations, or substitution mutations with linker sequences were introduced, and some viruses had higher viral titers than the others.
[0046] Example 2: Examination of the proliferation ability of VP6 mutant rotaviruses The proliferation ability of the nine VP6 mutant rotaviruses that showed high titers in Example 1 was compared in MA104 cells that persistently express VP6 and MA104 cells that do not express VP6 (hereinafter referred to as "normal MA104 cells"). <Materials and Methods> 7.5 × 10 VP6 persistently expressing MA104 cells and normal MA104 cells were cultured at 100°C. 4 Cells were seeded at 1000 cells / well in a 24-well culture plate and cultured overnight. The nine viruses selected in Example 1 were infected at an MOI of 0.01, respectively. 24 hours after infection, the medium and cells were frozen and thawed three times to prepare cell lysates, and the virus titer was measured. A wild-type virus lacking the VP6 mutation was used as a control. The virus titer was measured in the same manner as in Example 1.
[0047] <Results> The results are shown in Figure 3. All nine types of viruses used showed higher viral titers in MA104 cells with persistent VP6 expression than in normal MA104 cells. Of these, the virus (Δ169-174 + linker) that showed low proliferation in normal MA104 cells but efficiently propagated in MA104 cells with persistent VP6 expression was used in subsequent experiments.
[0048] Example 3: Comparison of proliferation ability between normal MA104 cells and MA104 cells continuously expressing VP6 The proliferation ability of the VP6 mutant rotavirus Δ169-174 + linker selected in Example 2 was compared between normal MA104 cells and MA104 cells continuously expressing VP6. <Materials and Methods> Normal MA104 cells and MA104 cells continuously expressing VP6 were cultured at 7.5 × 10 4 Cells were seeded at 1000 cells / well in a 24-well culture plate and cultured overnight. Δ169-174 + linker was infected at an MOI of 0.01. The medium and cells were freeze-thawed three times at 0, 24, 48, and 72 hours post-infection to prepare cell lysates and measure the virus titer. Wild-type virus lacking the VP6 mutation was used as a control. Virus titer measurement was performed in the same manner as in Example 1.
[0049] <Results> The results are shown in Figure 4. (A) shows the results for normal MA104 cells, and (B) shows the results for MA104 cells continuously expressing VP6. Δ169-174 + linker hardly grew in normal MA104 cells, but grew efficiently in MA104-VP6 cells.
[0050] Example 4: Examination of proliferation ability in normal MA104 cells To further confirm that the VP6 mutant rotavirus Δ169-174 + linker cannot proliferate in normal MA104 cells, it was subcultured in normal MA104 cells. <Materials and Methods> Normal MA104 cells were cultured at 3 × 10 5 Cells were seeded at 100 cells / well in a 6-well culture plate and cultured overnight. Δ169-174 + linker was infected at an MOI of 1.0. After one week of culture, the medium and cells were collected, frozen, and thawed to prepare a cell lysate. 10% of the resulting cell lysate was added to fresh normal MA104 cells and cultured for one week. The virus was passaged five times, and the virus titer was measured at each passage using the same method as in Example 1.
[0051] <Results> The results are shown in Figure 5. The titer of Δ169-174 + linker decreased with each passage, and the virus was not detected after the third passage. From these results, it was determined that Δ169-174 + linker is a single-pass infectious rotavirus that cannot grow in normal cells that do not express VP6.
[0052] Example 5: Examination of viral protein expression in normal cells. To use a single-infectious virus as a vaccine, normal cells that do not express VP6 must express viral proteins, even though they do not form infectious virus particles. Therefore, normal MA104 cells were infected with Δ169-174+linker, which was determined to be a single-infectious rotavirus in Example 3, and the expression of viral proteins was observed.
[0053] <Materials and Methods> Normal MA104 cells were cultured at 7.5 × 10 4Cells were seeded at 100 cells / well in 24-well culture plates containing coverslips and cultured overnight. Δ169-174 + linker and wild-type simian rotavirus (SA11 strain) were infected at an MOI of 1.0, respectively, and 8 hours later, the cells were fixed with formalin. The cells were permeabilized with 0.5% Triton-X and immunostained using rabbit anti-NSP4 and mouse anti-VP6 antibodies as primary antibodies, and CF488-labeled anti-rabbit IgG (BioTum) and CF594-labeled anti-mouse IgG (BioTum) as secondary antibodies. Nuclei were stained with Hoechst and observed under a fluorescence microscope.
[0054] <Results> The results are shown in Figure 6. When Δ169-174 + linker was infected into normal MA104 cells, viral protein expression was confirmed. This result indicates that Δ169-174 + linker is promising for use as a vaccine.
[0055] Example 6: Preparation of a single-pass infectious rotavirus containing a reporter gene 6-1 Single-pass infectious rotavirus expressing green fluorescent protein <Materials and methods> (1) Green fluorescent protein gene-inserted NSP1 expression plasmid The ZsGreen (hereinafter referred to as "ZsG") gene was used as the green fluorescent protein gene. The ZsG gene-inserted NSP1 gene expression plasmid used was pT7-NSP1-ZsG-Δ722 described by Kanai et al. (J Virol. 2019 Feb 15; 93(4): e01774-18.). pT7-NSP1-ZsG-Δ722 is a plasmid in which the ZsG gene is inserted between positions 111 and 112 of the NSP1 gene of pT7-NSP1SA11, and 722 nt (positions 134 to 855) is further deleted from the NSP1 gene.
[0056] (2) Preparation of single-episode infectious rotavirus expressing green fluorescent protein. Among the 11 types of segmented RNA genome expression vectors prepared in Example 1, pT7-VP6SA11 was replaced with pT7-VP6SA11 / Δ169-174+linker, and pT7-NSP1-ZsG-Δ722 was replaced with pT7-NSP1SA11. In addition to these, capping enzyme expression vectors (pCAGD1R and pCAG-D12L), rotavirus NSP2 expression vector (pCAG-NSP2SA11), rotavirus NSP5 expression vector (pCAG-NSP5SA11), and rotavirus VP6 expression vector (pcDNA3-VP6) were also introduced into BHK-T7 / P5 cells to prepare single-episode infectious rotavirus expressing green fluorescent protein, using the same procedure as in "Materials and Methods" (9) of Example 1. As a control, pT7-NSP1SA11, which does not contain ZsG, was used instead of pT7-NSP1-ZsG-Δ722 to generate a single-infectious rotavirus that does not express green fluorescent protein.
[0057] (3) Confirmation of ZsG Expression. MA104 cells persistently expressing VP6 were infected with the two viruses at an MOI of 1.0 and cultured for 8 hours. To confirm that green fluorescent cells were virus-infected, the expression of virus-derived NSP4 was confirmed. After 8 hours of culture, the cells were fixed with formalin. The cells were permeabilized with 0.5% Triton-X and stained with rabbit anti-NSP4 antibody as the primary antibody and CF594-labeled anti-rabbit IgG antibody (Biotum) as the secondary antibody. Nuclei were stained with Hoechst and observed under a fluorescence microscope.
[0058] <Results> The results are shown in Figure 7. It was confirmed that cells infected with ZsG-introduced, monoinfectious rotavirus (Δ169-174 + linker) emitted green fluorescence.
[0059] 6-2 Luciferase-Expressing Single-Infectious Rotavirus <Materials and Methods> (1) Luciferase Gene-Inserted NSP1 Expression Plasmid The luciferase gene used was the NanoLuc (NLuc) gene, a luciferase gene derived from the giant shrimp Oplophorus gracilirostris. The NLuc gene-inserted NSP1 gene expression plasmid used was pT7-NSP1-NLuc-Δ722, described by Kanai et al. (J Virol. 2019 Feb 15; 93(4): e01774-18.). pT7-NSP1-NLuc-Δ722 is a plasmid in which the NLuc gene has been inserted between positions 111 and 112 of the NSP1 gene of pT7-NSP1SA11, and 722 nt (positions 134 to 855) has been deleted from the NSP1 gene.
[0060] (2) Preparation of luciferase-expressing, single-infectious rotaviruses. Of the 11 types of segmented RNA genome expression vectors prepared in Example 1, pT7-VP6SA11 was replaced with pT7-VP6SA11 / Δ169-174+linker, and pT7-NSP1-NLuc-Δ722 was replaced with pT7-NSP1SA11. In addition to these, capping enzyme expression vectors (pCAGD1R and pCAG-D12L), rotavirus NSP2 and NSP5 expression vectors (pCAG-NSP2SA11 and pCAG-NSP5SA11), and a rotavirus VP6 expression vector (pcDNA3-VP6) were also introduced into BHK-T7 / P5 cells to prepare NLuc-expressing, single-infectious rotaviruses using the same procedures as those described in "Materials and Methods" (9) of Example 1. As a control, pT7-NSP1SA11 containing no NLuc was used instead of pT7-NSP1-NLuc-Δ722.
[0061] (3) Luciferase activity measurement: 1 × 10 MA104 cells continuously expressing VP6 4Cells were seeded at 1000 cells / well in a 96-well culture plate and cultured overnight. The cells were infected with the NLuc-expressing single-infective rotavirus prepared in (2) at an MOI of 0.01. The medium and cells were collected over time, frozen, and thawed to prepare cell lysates. Luciferase activity in the cell lysates was measured using the Nano-Glo Luciferase Assay System (Promega).
[0062] <Results> The results are shown in Figure 8. It was shown that the luciferase activity of the NLuc-expressing, single-infectious rotavirus increased over time after infection.
[0063] Example 7 Neutralization Test Using Luciferase-Expressing Single-Infectious Rotavirus Materials and Methods (1) Luciferase-Expressing Single-Infectious Rotavirus The NLuc-expressing single-infectious rotavirus prepared in Example 6-2 was used. As a control, an NLuc-expressing self-replicating rotavirus was used, which was prepared by replacing pT7-VP6SA11 / Δ169-174+linker with pT7-VP6SA11, which does not have a mutation in VP6, in the NLuc-expressing single-infectious rotavirus prepared in Example 6-2. The viral titers of both viruses were measured, and viruses with a titer of 100 FFU were prepared from each.
[0064] (2) Serum: Anti-rSA11 serum was used, as described by Kanai et al. (J Virol. 2020 Dec 22;95(2):e01374-20.). Anti-rSA11 serum was prepared by injecting wild-type SA11 strain into BALB / c mice (male, 3 weeks old) at 1.0 × 10 6 The serum was obtained by oral administration at FFU / animal, and the administration was repeated seven times at two-week intervals, followed by blood sampling.
[0065] (3) Neutralization test: 1 × 10 MA104 cells continuously expressing VP6 4Cells were seeded at 100 cells / well in a 96-well culture plate and cultured overnight. The serum from (2) was serially diluted and mixed with 100 FFU of the virus prepared in (1) and incubated at 37°C for 1 hour. Each virus-serum mixture was then added to the cells and cultured for 24 hours. The medium and cells were collected and frozen / thawed. The luciferase activity of the prepared cell lysates was measured using the Nano-Glo Luciferase Assay System. The neutralization rate was calculated as the percentage reduction in luciferase activity compared to the luciferase activity of a serum-free control.
[0066] <Results> The results are shown in Figure 9. The results of the neutralization test using luciferase-expressing, single-infectious rotavirus were comparable to those using luciferase-expressing, self-replicating rotavirus. Conventional neutralization tests generally involve visually counting virus-infected cells under a microscope, which requires cumbersome, time-consuming procedures and results that vary significantly depending on the individual performing the test. Furthermore, the use of infectious viruses requires P2-level facilities. The results of this example demonstrate that the use of reporter gene-expressing, single-infectious rotavirus in neutralization tests allows for safe, simple neutralization tests with minimal variation.
[0067] Example 8: Preparation of a single-episode infectious rotavirus containing a human rotavirus coat protein. Although the SA11 strain is a simian rotavirus, when using a single-episode infectious rotavirus as a vaccine or antigen for neutralization tests, it is desirable to have a human rotavirus coat protein. Therefore, Kanai et al. (J. Virol. 2020 Dec 22;95(2):e01374-20.) attempted to prepare a single-episode infectious rotavirus containing a segmented RNA genome encoding VP7 of a human rotavirus isolated from the feces of nine children with acute gastroenteritis in Japan. VP7 is the coat protein located in the outermost layer of the virus particle and is responsible for the antigenicity and immunogenicity of the virus (see Figure 13(A)).
[0068] <Materials and Methods> Of the 11 types of segmented RNA genome expression vectors prepared in Example 1, pT7-VP6Δ169-174+linker encoding the mutated VP6 was used instead of pT7-VP6SA11, and pT7-hVP7, a segmented RNA genome expression vector encoding human rotavirus VP7, was used instead of pT7-VP7SA11. In addition to these, capping enzyme expression vectors (pCAGD1R and pCAG-D12L), rotavirus NSP2 and NSP5 expression vectors (pCAG-NSP2SA11 and pCAG-NSP5SA11), and a rotavirus VP6 expression vector (pcDNA3-VP6) were also introduced into BHK-T7 / P5 cells to prepare single-episode infectious rotaviruses carrying human rotavirus VP7 using a procedure similar to that described in "Materials and Methods" (9) of Example 1. Five types of human rotaviruses with VP7 genotypes (serotypes) G1, G2, G3, G8, and G9 were used, and the segmented RNA genomes encoding VP7 obtained from each of these five human rotaviruses were used (Kanai et al., J Virol. 2020 Dec 22;95(2):e01374-20.).
[0069] The virus titers of the five types of single-infectious rotaviruses (Δ169-174 + linker / G1, Δ169-174 + linker / G2, Δ169-174 + linker / G3, Δ169-174 + linker / G8, and Δ169-174 + linker / G9) containing segmented RNA genomes encoding human rotavirus VP7 and the SA11 strain single-infectious rotavirus (Δ169-174 + linker) were calculated using the same method as in "Materials and Methods" (10) of Example 1.
[0070] <Results> The results are shown in Figure 10. It was demonstrated that single-infectious rotaviruses could be produced using plasmids carrying VP7 from human rotaviruses of each genotype.
[0071] [Example 9: Neutralization test using single-infectious rotavirus expressing human rotavirus VP7] A neutralization test was performed to analyze whether the antigenicity of single-infectious rotaviruses expressing human rotavirus VP7 of different genotypes (serotypes) differs.
[0072] <Materials and Methods> (1) Single-episode infectious rotaviruses containing human rotavirus VP7. The single-episode infectious rotaviruses expressing human rotavirus VP7 were Δ169-174+linker / G1, Δ169-174+linker / G3, Δ169-174+linker / G8, and Δ169-174+linker / G9, which have different VP7 genotypes (serotypes) and were prepared in Example 8. As controls, SA11 single-episode infectious rotavirus Δ169-174+linker and wild-type SA11 were used. The viral titer of each virus was measured, and a virus with a titer of 100 FFU was prepared.
[0073] (2) Serum: Anti-rSA11 serum was used, as described by Kanai et al. (J Virol. 2020 Dec 22;95(2):e01374-20.). Anti-rSA11 serum was prepared by injecting wild-type SA11 strain into BALB / c mice (male, 3 weeks old) at 1.0 × 10 6 The serum was obtained by oral administration at FFU / animal, repeated seven times at two-week intervals, followed by blood sampling. The wild-type SA11 strain VP7 genotype (serotype) is G3.
[0074] (3) Neutralization test: 1 × 10 MA104 cells continuously expressing VP6 4Cells were seeded at 100 cells / well in a 96-well culture plate and cultured overnight. The serum from (2) was serially diluted and mixed with 100 FFU of the virus prepared in (1) and incubated at 37°C for 1 hour. After incubation, each virus-serum mixture was added to the cells and culture was initiated. After 18 hours, the cells were fixed with formalin, permeabilized with 0.5% Triton-X, and infected cells were visualized and counted by immunofluorescence. The primary antibody used in the immunofluorescence assay was a rabbit anti-rotavirus NSP4 antibody, and the secondary antibody was a CF488-conjugated anti-rabbit IgG antibody (Biotum). The neutralization rate was calculated as the percentage reduction in infected cells compared to the number of infected cells in a serum-free control.
[0075] <Results> The results are shown in Figure 11. The wild-type SA11 strain (genotype G3), the single-infectious rotavirus Δ169-174 + linker (genotype G3) expressing the SA11 strain VP7, and the single-infectious rotavirus Δ169-174 + linker / G3 expressing the G3 human VP7 were efficiently neutralized by serum immunized with the wild-type SA11 strain (genotype G3). In contrast, the single-infectious rotaviruses expressing human VP7 genotypes other than G3 showed low neutralizing activity. These results indicate that single-infectious rotaviruses expressing VP7 from human rotaviruses of different genotypes have different antigenicities. Therefore, it was confirmed that single-infectious rotaviruses with different antigenicities can be produced.
[0076] Example 10: Vaccine effect of single-infectious rotavirus Materials and methods (1) Vaccine administration to mice Three groups were established: a group administered Δ169-174 + linker, a single-infectious rotavirus SA11 strain, a group administered wild-type SA11 strain (positive control), and a group administered PBS (negative control). BALB / c mice (female, 4 weeks old, n = 5-6 per group) were administered concentrated virus (1.0 × 10 7 The mice were orally administered either 0.05% FFU / mouse or PBS. The mice were immunized three times at three-week intervals, and blood samples were collected two weeks after each immunization, and the serum samples were used for a neutralization test.
[0077] (2) Neutralization test: 1 x 10 normal MA104 cells 4Cells were seeded at 100 cells / well in a 96-well culture plate and cultured overnight. Serially diluted mouse serum was mixed with 100 FFU of NLuc-expressing self-replicating rotavirus (see Example 7) and incubated at 37°C for 1 hour. The virus-serum mixture was then added to the cells and cultured for 24 hours. The medium and cells were collected and frozen / thawed. The luciferase activity of the prepared cell lysates was measured using the Nano-Glo Luciferase Assay System. The neutralization rate was calculated as the percentage reduction in luciferase activity compared to the luciferase activity of a serum-free control. The serum dilution showing 50% neutralization (NT50) was also calculated. A higher NT50 value indicates higher neutralizing activity. Statistical analysis was performed using the Mann-Whitney U test. A P value of 0.05 or less was considered significant.
[0078] <Results> The results are shown in Figure 12. (A) shows the NT50 of the serum after the first immunization, (B) shows the NT50 of the serum after the second immunization, and (C) shows the NT50 of the serum after the third immunization. At any time point, there was no significant difference between the single-infectious rotavirus group and the wild-type SA11 strain group, demonstrating that the single-infectious rotavirus exerts a vaccine effect equivalent to that of wild-type rotavirus.
[0079] Example 11: Propagation of single-infectious rotavirus infecting mice Materials and methods Two groups were established: a group administered with Δ169-174 + linker, a single-infectious rotavirus of the SA11 strain (single-infectious virus group), and a group administered with the wild-type SA11 strain (wild-type virus group). Concentrated virus (1 × 10 7The mice were orally administered 100 mg of rotavirus (FFU / animal). Two days later, the intestines were collected, and the cecum was excised and processed using a bead homogenizer. RNA was extracted from the obtained cecal samples using Trizol reagent (Invitrogen), and the viral RNA copy number was measured by qRT-PCR. For qRT-PCR, a Thunderbird probe One-step qRT-PCR kit (Toyobo) was used. The following primer-probe set was used to detect the VP1 segment of rotavirus: Forward: AGGCAAACCATTGGAGGCAGAC (SEQ ID NO: 14) Reverse: CCAACCAGAACATGACTGCATT (SEQ ID NO: 15) Probe: FAM-TCCAACAGCGGAGGAATATACGGAC-TAMRA (SEQ ID NO: 16)
[0080] In addition, cecal samples were added to the culture medium of VP6-expressing MA104 cells, and the cells were infected with the virus, and the virus titer was measured. A t-test was performed to determine the viral RNA copy number, and a Mann-Whitney U test was performed to determine the virus titer. A p value of 0.05 or less was considered significant.
[0081] <Results> The results are shown in Figure 14. (A) shows the viral RNA copy number, and (B) shows the results of infectious virus detection. When comparing the wild-type virus group (WT) and the single-infectious virus group (Δ169-174 + linker), there was no statistically significant difference in copy number, but the wild-type virus tended to have a higher copy number, suggesting that the virus was replicating. Infectious virus detection showed significantly higher viral titers for the wild-type virus than for the single-infectious virus. Specifically, infectious virus was detected in 7 / 19 mice in the wild-type virus group and 0 / 18 mice in the single-infectious virus group. These results suggest that the single-infectious virus cannot replicate in mice.
[0082] [Example 12: Production of single-infectious rotavirus by VP7 mutation introduction] <Materials and methods> A single-infectious rotavirus was produced by changing the mutated gene from VP6 to VP7 and changing the VP6 expression vector to a VP7 expression vector in the method for producing a single-infectious rotavirus in Example 1. The materials not used in Example 1 are listed below.
[0083] (1) Rotavirus VP7 Expression Vector The VP7 expression vector, pcDNA3-VP7, was prepared by inserting the protein-coding region DNA of the SA11 strain VP7 gene (SEQ ID NO: 9) into the BamHI and EcoRI sites of the pcDNA3.1(+) plasmid. The coding region DNA was synthesized using an artificial gene synthesis service (GenScript).
[0084] (2) VP7 Mutation-Introducing Plasmids Five types of plasmids were constructed by introducing deletion mutations into the cDNA of the rotavirus VP7 RNA genome contained in pT7-VP7SA11 using known genetic recombination techniques. The structure of rotavirus VP7 and the various mutated regions are shown in Figure 15.
[0085] (3) VP7-sustained expression cells. The rotavirus VP7 gene was introduced into the pLVSIN-CMV-Neo vector (Takara Bio) and co-transfected with psPAX2 (Addgene) and pCMV-VSV-G (Addgene) into 293T cells to generate lentivirus. The resulting lentivirus was then infected into African green monkey MA104 cells (ATCC CRL-2378.1). After two days, drug selection was performed with G418 (800 μg / mL). From the VP7-expressing MA104 cells obtained through drug selection, cells with persistently strong VP7 expression were cloned by limiting dilution.
[0086] <Results> The results are shown in Table 3. Artificial recombinant viruses were successfully produced using a VP7 mutation introduction plasmid (pT7-VP7SA11-Δdomain II) in which domain II of VP7 was deleted, and a VP7 mutation introduction plasmid (pT7-VP7SA11-250bp) in which 250 bp at each end of the VP7 gene was retained. The viral titer was higher for the artificial recombinant virus in which domain II of VP7 was deleted (VP7-ΔDomain II). VP7-ΔDomain II was used in subsequent experiments.
[0087]
[0088] Example 13: Comparison of proliferation ability between normal MA104 cells and MA104 cells continuously expressing VP7 The proliferation ability of normal MA104 cells and MA104 cells continuously expressing VP7 was compared for the VP7 mutant rotavirus VP7-ΔDomain II prepared in Example 12. <Materials and Methods> Normal MA104 cells and MA104 cells continuously expressing VP7 were cultured at 7.5 × 10 4 Cells were seeded at 1000 cells / well in a 24-well culture plate and cultured overnight. VP7-ΔDomain II was infected at an MOI of 0.01. The medium and cells were freeze-thawed three times at 0, 24, 48, and 72 hours post-infection to prepare cell lysates and measure the virus titer. Wild-type virus lacking the VP7 mutation was used as a control. Virus titer measurement was performed as described in Example 1.
[0089] <Results> The results are shown in Figure 16. (A) shows the results for normal MA104 cells, and (B) shows the results for MA104 cells continuously expressing VP7. VP7-ΔDomain II hardly proliferated in normal MA104 cells, but proliferated efficiently in MA104-VP7 cells.
[0090] Example 14: Examination of proliferation ability in normal MA104 cells To further confirm that the VP7 mutant rotavirus VP7-ΔDomain II cannot proliferate in normal MA104 cells, it was subcultured in normal MA104 cells. <Materials and Methods> Normal MA104 cells were cultured at 1.5 × 10 5Cells were seeded at 12-well culture plates at 100 cells / well and cultured overnight. VP7-ΔDomain II was infected at an MOI of 1.0. After one week of culture, the medium and cells were collected, frozen, and thawed to prepare a cell lysate. 10% of the resulting cell lysate was added to fresh normal MA104 cells and cultured for one week. The virus was passaged five times, and the virus titer was measured at each passage using the same method as in Example 1.
[0091] <Results> The results are shown in Figure 17. The titer of VP7-ΔDomain II decreased with each passage, and virus was not detected after the second passage. From these results, we concluded that VP7-ΔDomain II is a single-pass infectious rotavirus that cannot grow in normal cells that do not express VP7.
[0092] Example 15: Construction of a single-infectious rotavirus by VP4 mutation introduction Materials and methods: A single-infectious rotavirus was constructed by using the method for constructing a single-infectious rotavirus in Example 1, except that the gene used for the mutation introduction was changed from VP6 to VP4, and the VP6 expression vector was changed to a VP4 expression vector. Materials not used in Example 1 are listed below. (1) Rotavirus VP4 expression vector: The VP4 expression vector, pcDNA3-VP4, was constructed by inserting the protein-coding region DNA of the VP4 gene (SEQ ID NO: 4) of the SA11 strain into the BamHI and EcoRI cleavage sites of the pcDNA3.1(+) plasmid. The coding region DNA was synthesized using an artificial gene synthesis service (GenScript).
[0093] (2) VP4 Mutation-Introducing Plasmids Three types of plasmids were constructed by introducing deletion mutations into the cDNA of the rotavirus VP4 RNA genome contained in pT7-VP4SA11 using known genetic recombination techniques. The structure of rotavirus VP4 and the various mutated regions are shown in Figure 18.
[0094] (3) VP4-persistently expressing cells. The rotavirus VP4 gene was introduced into the pLVSIN-CMV-Neo vector (Takara Bio) and co-transfected with psPAX2 (Addgene) and pCMV-VSV-G (Addgene) into 293T cells to generate lentivirus. The lentivirus was then infected into African green monkey MA104 cells (ATCC CRL-2378.1), and after two days, drug selection was performed with G418 (800 μg / mL). From the VP4-expressing MA104 cells obtained by drug selection, cells with persistently strong VP4 expression were cloned by limiting dilution.
[0095] <Results> The results are shown in Table 4. Artificial recombinant viruses were successfully generated using the VP4 mutation introduction plasmid (pT7-VP4SA11-ΔLectin) in which the VP4 lectin domain was deleted, the VP4 mutation introduction plasmid (pT7-VP4SA11-Δβ-Barrel) in which the VP4 β-barrel domain was deleted, and the VP4 mutation introduction plasmid (pT7-VP4SA11-120bp) in which 120 bp at each end of the VP4 gene was retained. The larger the deletion region, the less likely reversion mutation occurs and the easier it is to introduce a foreign gene; therefore, VP4-120bp was used in subsequent experiments.
[0096]
[0097] Example 16: Comparison of proliferation ability between normal MA104 cells and MA104 cells continuously expressing VP4 The proliferation ability of the VP4 mutant rotavirus VP4-120bp prepared in Example 15 was compared between normal MA104 cells and MA104 cells continuously expressing VP4. <Materials and Methods> Normal MA104 cells and MA104 cells continuously expressing VP4 were cultured at 7.5 × 10 4 Cells were seeded at 1000 cells / well in a 24-well culture plate and cultured overnight. VP4-120bp was infected at an MOI of 0.01. The medium and cells were freeze-thawed three times at 0, 24, 48, and 72 hours post-infection to prepare cell lysates and measure the virus titer. Wild-type virus lacking the VP4 mutation was used as a control. Virus titer measurement was performed in the same manner as in Example 1.
[0098] <Results> The results are shown in Figure 19. (A) shows the results for normal MA104 cells, and (B) shows the results for MA104 cells continuously expressing VP4. VP4-120bp hardly grew in normal MA104 cells, but grew efficiently in MA104-VP4 cells.
[0099] Example 17: Examination of proliferation ability in normal MA104 cells To further confirm that the VP4 mutant rotavirus VP4-120bp cannot proliferate in normal MA104 cells, it was subcultured in normal MA104 cells. <Materials and Methods> Normal MA104 cells were cultured at 1.5 × 10 5 Cells were seeded at 12 cells / well in a 12-well culture plate and cultured overnight. VP4-120bp was infected at an MOI of 1.0. After one week of culture, the medium and cells were collected, frozen, and thawed to prepare a cell lysate. 10% of the resulting cell lysate was added to fresh normal MA104 cells and cultured for one week. The virus was passaged five times, and the virus titer was measured at each passage using the same method as in Example 1.
[0100] <Results> The results are shown in Figure 20. The titer of VP4-120bp decreased with passage, and the virus was not detected after the second passage. From these results, it was determined that VP4-120bp is a single-pass infectious rotavirus that cannot grow in normal cells that do not express VP4.
[0101] Example 18: Construction of a single-episode infectious rotavirus carrying a foreign gene in the VP4 segment 18-1 Green fluorescent protein-expressing single-episode infectious rotavirus Materials and Methods (1) Construction of a green fluorescent protein-expressing single-episode infectious rotavirus The ZsG gene was used as the green fluorescent protein gene. A ZsG expression plasmid was constructed by inserting the foot-and-mouth disease virus (FMDV) 2A sequence (self-cleavage sequence) and the ZsG gene immediately after the 120 bp at the 5' end of the pT7-VP4SA11-120bp plasmid. A ZsG-expressing single-episode infectious rotavirus was constructed using the same method as in Example 15. As controls, a wild-type artificial recombinant rotavirus was constructed using a plasmid (pT7-VP4SA11) encoding the wild-type VP4 segment, and a VP4-deleted artificial recombinant rotavirus (single-episode infectious rotavirus) was constructed using pT7-VP4SA11-120bp without the ZsG gene.
[0102] (2) Confirmation of ZsG Expression. Conventional MA104 cells were infected with the prepared virus at an MOI of 1.0 and cultured for 8 hours. To confirm that green fluorescent cells were virus-infected, the expression of virus-derived NSP4 was confirmed. After 8 hours of culture, the cells were fixed with formalin. The cells were permeabilized with 0.5% Triton-X and stained with rabbit anti-NSP4 antibody as the primary antibody and CF594-labeled anti-rabbit IgG antibody (Biotum) as the secondary antibody. Nuclei were stained with Hoechst and observed under a fluorescence microscope.
[0103] <Results> The results are shown in Figure 21. It was confirmed that cells infected with the ZsG-introduced, monoinfectious rotavirus (VP4-120-ZsG) emitted green fluorescence.
[0104] 18-2 Luciferase-Expressing Single-Pass Infectious Rotavirus <Materials and Methods> (1) Luciferase Gene-Inserted NSP1 Expression Plasmid The NLuc gene was used as the luciferase gene. An NLuc expression plasmid was constructed by inserting the foot-and-mouth disease virus (FMDV) 2A sequence (self-cleavage sequence) and the NLuc gene immediately after the 120 bp at the 5' end of the pT7-VP4SA11-120bp plasmid. NLuc-expressing single-pass infectious rotavirus was constructed using the same method as in Example 15. As a control, a VP4-deleted single-pass infectious rotavirus was constructed using pT7-VP4SA11-120bp without the NLuc gene inserted.
[0105] (2) Luciferase activity measurement: 1 × 10 normal MA104 cells 4 MA104 cells were seeded at 120 cells / well in a 96-well culture plate and cultured overnight. The resulting NLuc-expressing single-infectious rotavirus and VP4-deleted single-infectious rotavirus were infected at an MOI of 0.1. The medium and cells were collected over time, frozen, and thawed to prepare cell lysates. MA104 cells cultured in trypsin-supplemented medium (VP4-120-NLuc+Trypsin) were used for infection with the NLuc-expressing single-infectious rotavirus. Luciferase activity in the cell lysates was measured using the Nano-Glo Luciferase Assay System (Promega).
[0106] <Results> The results are shown in Figure 22. It was shown that luciferase activity of NLuc-expressing, singly infectious rotavirus increased over time after infection. Furthermore, there was no difference in luciferase activity in the presence or absence of trypsin. Trypsin is an enzyme necessary for rotavirus infectivity. Therefore, in the case of a replicative virus, secondary and tertiary infections occur in the presence of trypsin, and luciferase activity increases in the presence of trypsin compared with its absence 24 hours after infection. However, in this experiment, there was no difference even after 24 hours, indicating that infectious virus was not produced and that the virus was singly infectious.
[0107] Example 19: Preparation of VP4-deleted, single-episode infectious rotavirus having the outer coat protein of human rotavirus As in Example 8, a single-episode infectious rotavirus having a segmented RNA genome encoding VP7 of the human rotavirus isolated from the stool of nine children with acute gastroenteritis in Japan by Kanai et al. (J Virol. 2020 Dec 22;95(2):e01374-20.) was prepared.
[0108] <Materials and Methods> Of the 11 types of segmented RNA genome expression vectors prepared in Example 1, pT7-VP4SA11-120bp, encoding the mutated VP4, was used instead of pT4-VP6SA11, and pT7-hVP7, a segmented RNA genome expression vector encoding human rotavirus VP7, was used instead of pT7-VP7SA11. In addition to these, capping enzyme expression vectors (pCAGD1R and pCAG-D12L), rotavirus NSP2 and NSP5 expression vectors (pCAG-NSP2SA11 and pCAG-NSP5SA11), and a rotavirus VP4 expression vector (pcDNA3-VP4) were also introduced into BHK-T7 / P5 cells to prepare VP4-deleted, single-infectious rotaviruses carrying human rotavirus VP7 using a procedure similar to that described in "Materials and Methods" (9) of Example 1. Four types of human rotaviruses with VP7 genotypes (serotypes) G1, G2, G8, and G9 were used, and VP7-encoding RNA genomes obtained from each of these four types of human rotaviruses were used (Kanai et al., J Virol. 2020 Dec 22;95(2):e01374-20.). The viral titers of the four VP4-deleted single-infectious rotaviruses (VP4-120bp / G1, VP4-120bp / G2, VP4-120bp / G8, and VP4-120bp / G9) containing the resulting RNA genomes encoding human rotavirus VP7 were calculated using the same method as in Example 1.
[0109] <Results> The results are shown in Table 5. Using plasmids carrying VP7 from human rotavirus of each genotype, we were able to generate VP4-deleted single-infectious rotaviruses carrying human rotavirus coat proteins. These single-infectious rotaviruses expressing VP7 from human rotaviruses of different genotypes are antigenically distinct single-infectious rotaviruses (see Example 9).
[0110]
[0111] Example 20: Construction of a single-episode infectious rotavirus carrying the novel coronavirus spike protein gene in the VP4 segment. Materials and Methods: (1) Construction of a single-episode infectious rotavirus expressing the novel coronavirus spike protein. The foreign gene used was a gene encoding the receptor-binding domain (RBD) of the novel coronavirus (SARS-CoV-2) spike protein. The novel coronavirus RBD gene was amplified from the spike protein expression plasmid described by Minami et al. (Microbiol Spectr. 2024 Apr 2;12(4):e0285923.). A plasmid was constructed by inserting the foot-and-mouth disease virus (FMDV) 2A sequence (self-cleavage sequence) and the novel coronavirus RBD gene immediately after the 120 bp at the 5' end of the pT7-VP4SA11-120bp plasmid. A single-episode infectious rotavirus expressing the novel coronavirus RBD was constructed using the same method as in Example 15. As a control, a VP4-deleted, single-infectious rotavirus was constructed using pT7-VP4SA11-120bp, which did not contain the RBD gene.
[0112] (2) Confirmation of RBD Expression. Conventional MA104 cells were infected with the prepared virus at an MOI of 1.0 and cultured for 16 hours. After culture, cell lysates were prepared using RIPA buffer, and protein expression was confirmed by Western blotting. Proteins were separated by SDS-PAGE using a 10% polyacrylamide gel and transferred to a PVDF membrane. After blocking with 3% skim milk, the cells were incubated with rabbit anti-SARS-CoV-2 RBD antibody (Sino Biological), rabbit anti-rotavirus NSP3 antibody, or mouse anti-β-actin antibody (Sigma-Aldrich) as primary antibodies. HRP-conjugated anti-rabbit IgG antibody (Nacalai Tesque) or HRP-conjugated anti-mouse antibody (Nacalai Tesque) were used as secondary antibodies. Chemi-Lumi-One Ultra (Nacalai Tesque) was used for color development. Images were captured using a chemiluminescence imaging system.
[0113] <Results> The results are shown in Figure 23. Cells infected with a single-infectious rotavirus (VP4-single-RBD) carrying the receptor-binding domain (RBD) of the spike protein of the novel coronavirus (SARS-CoV-2) were confirmed to express RBD.
[0114] The present invention is not limited to the above-described embodiments and examples, and various modifications are possible within the scope of the claims. The technical scope of the present invention also includes embodiments obtained by appropriately combining the technical means disclosed in different embodiments. Furthermore, all academic literature and patent documents described in this specification are incorporated herein by reference.
Claims
1. A monoinfectious rotavirus characterized by having a mutation in at least one viral protein selected from the group consisting of rotavirus VP1, VP2, VP3, VP4, VP6, VP7, NSP2, NSP3 and NSP4.
2. The mono-infectious rotavirus of claim 1, which has a mutation that induces dysfunction of a structural protein.
3. The monoinfectious rotavirus of claim 1, having a mutation in VP6.
4. A monoinfectious rotavirus according to claim 3, having a mutation in domain H of VP6.
5. The mono-infectious rotavirus of claim 4, which has a mutation in the A'-A'' loop, the D'-D'' loop or the αA-I loop of domain H of VP6.
6. The monoinfectious rotavirus of claim 1, having a mutation in VP4.
7. A monoinfectious rotavirus according to claim 6, having a mutation that deletes the lectin domain and / or the β-barrel domain of VP4.
8. The monoinfectious rotavirus of claim 1, which has a mutation in VP7.
9. A monoinfectious rotavirus according to claim 8, having a mutation that deletes domain II of VP7.
10. The monoinfectious rotavirus of claim 1 which is a reassortant.
11. A monoinfectious rotavirus according to claim 1 which is a reassortant having a segmented RNA genome encoding structural proteins of a different genotype or of a different strain than the parent strain.
12. The monoinfectious rotavirus of claim 1 which is a reassortant having a segmented RNA genome encoding the structural proteins of human rotavirus.
13. The monoinfectious rotavirus of claim 1, which expresses a foreign gene.
14. The mono-infectious rotavirus according to claim 13, wherein the foreign gene is a gene encoding an antigenic protein of a virus or a pathogenic microorganism other than rotavirus.
15. The monoinfectious rotavirus of claim 13, wherein the foreign gene is a reporter gene.
16. The monoinfectious rotavirus of claim 15, wherein the reporter gene is a gene encoding a fluorescent protein or a chemiluminescent protein.
17. A vaccine containing a monoinfectious rotavirus according to any one of claims 1 to 14.
18. The vaccine of claim 17 which is a rotavirus vaccine.
19. A method for neutralizing a rotavirus, comprising using a single-infectious rotavirus according to any one of claims 1 to 16.
Citation Information
Patent Citations
vaccination
JP2003507040A
Rotavirus VP7 fusion proteins and rotavirus-like particles containing them
JP2022521217A
Method for preparing artificial recombinant rotavirus
WO2018062199A1
